Evidence map›Paper›PMID 15824927›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2005

Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction.

Riemer H J A Slart, Jeroen J Bax, Jaep de Boer, Antoon T M Willemsen, Piet H Mook, Matthijs Oudkerk, Ernst E van der Wall, Dirk J van Veldhuisen, Pieter L Jager

Abstract readClinical TrialComparative StudyControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Influence of spill-over forPhysical and engineering sciences in medicine · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Positron emission tomography; viable tool in patients pre-CABG?The international journal of cardiovascular imaging · 2010
    Article
  9. Article
  10. Article
  11. The promise of I-123 radiotracers.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Riemer H J A SlartDepartment of Nuclear Medicine and Molecular Imaging, Groningen University Medical Center, Hanzeplein 1, P.O. Box 30001, 9700 RB, Groningen, The Netherlands. r.slart@nucl.umcg.nl
Jeroen J Bax
Jaep de Boer
Antoon T M Willemsen
Piet H Mook
Matthijs Oudkerk
Ernst E van der Wall
Dirk J van Veldhuisen
Pieter L Jager

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDual-isotope simultaneous acquisition (DISA) single-photon emission computed tomography (SPECT) is an attractive technique as it permits assessment of both myocardial glucose metabolism and perfusion within a single session, but few data on its accuracy for the assessment of viability are available as yet. In the present study, DISA SPECT was compared with positron emission tomography (PET) for the detection of myocardial viability in normal and dysfunctional left ventricular (LV) myocardium.

methodsFifty-eight patients with chronic coronary artery disease and LV dysfunction (LV ejection fraction 33+/-12%) were studied. Patients underwent a 1-day dipyridamole stress 99mTc-sestamibi/18F-fluorodeoxyglucose (18FDG) DISA SPECT and 13N-ammonia/18FDG PET protocol. Within 1 week, resting MRI was performed to assess contractile function. Comparison of PET and SPECT data was performed using both visual and quantitative analysis.

resultsThe correlation of normalised activities of the flow tracers 99mTc-sestamibi and 13N-ammonia was good (r = 0.82; p < 0.001). The correlation between the two 18FDG studies was also good (r = 0.83; p < 0.001). The agreement for the assessment of viability for all segments between DISA SPECT and PET was 82%, with a kappa-statistic of 0.59 (95% CI 0.53-0.64), without a significant difference; in dysfunctional segments only, the agreement was 82%, with a kappa-statistic of 0.63 (95% CI 0.56-0.70), without a significant difference. When the DISA SPECT data were analysed visually, the agreement between DISA SPECT and PET was 83%, with a kappa-statistic of 0.58 (95% CI 0.52-0.63), without a significant difference. Moreover, there was no significant difference between visual and quantitative DISA SPECT analysis for the detection of viability.

conclusionThis study shows an overall good agreement between 99mTc-sestamibi/18FDG DISA SPECT and PET for the assessment of myocardial viability in patients with severe LV dysfunction. Quantitative or visual analysis of the SPECT data did not influence the agreement with PET, suggesting that visual assessment may be sufficient for clinical purposes.

Indexed as

Fluorodeoxyglucose F18Technetium Tc 99m SestamibiAdultAgedAged, 80 and overCoronary Artery DiseaseFemaleHumansImage EnhancementMaleMiddle AgedMyocardial StunningPositron-Emission TomographyRadiopharmaceuticalsReproducibility of ResultsSensitivity and SpecificityFluorodeoxyglucose F18RadiopharmaceuticalsTechnetium Tc 99m Sestamibi

Identifiers

PMID15824927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.